Gastric ulcer
Gastric ulcer is a type of peptic ulcer, that is, a chronic ulcer that occurs in the stomach and duodenum. It is a common disease. There are various factors that cause ulcers, among which the digestive effect of acidic gastric juice on the mucosa is the basic factor in the formation of ulcers. Any part of the body that is exposed to acidic gastric juice, such as the lower esophagus, the anastomosis after gastrointestinal anastomosis, the jejunum, and the Meckel diverticulum with ectopic gastric mucosa. The vast majority of ulcers occur in the duodenum and stomach, so it is also called gastric/duodenal ulcer. Among them, delayed gastric emptying and bile reflux, abnormal effects of gastrointestinal peptides, genetic factors, drug factors (such as aspirin, many anti-inflammatory analgesics, etc.), environmental factors and mental factors are all related to the occurrence of gastric ulcers. The main manifestations are upper abdominal pain, dull pain, distending pain, burning pain or hunger pain. About 10% of the population has suffered from peptic ulcers in their lifetime. This disease can be seen at any age, mostly between 20 and 50 years old, and more men than women.
-
Site of disease:
Stomach -
Infectious :
Not contagious -
Frequent population:
The incidence rate in men is significantly higher than that in women -
Related symptoms:
Loss of appetite stomach heat pain upper abdominal discomfort indigestion excessive stomach acid -
Concurrent disease:
Related Drugs
Ranitidine Hydrochloride Capsules
Indication: Used to treat duodenal ulcer, gastric ulcer, reflux esophagitis, Zollinger-Ellison syndrome and other high gastric acid secretion diseases.
Manufacturer:
Shandong Lukang Group Saite Co., Ltd.
OMEPRAZOLE- omeprazole_capsule, delayed release
Indication: Omeprazole is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults (1. 1) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1. 2) Treatment of active benign gastric ulcer in adults (1. 3) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1. 4) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1. 6) Pathologic hypersecretory conditions in adults (1. 7) Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. Eradication of H. pylori Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12. 4) Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e. , heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e. , Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.
Manufacturer:
REMEDYREPACK INC.
Related Ingredients